President Trump Approves Plan to Dismiss FDA Commissioner Marty Makary Amid Controversies
President Donald Trump has reportedly approved a plan to dismiss FDA Commissioner Marty Makary, following a period marked by contentious drug rejections and internal conflicts within the agency. The decision, reported by The Wall Street Journal, comes after Makary defended the FDA's rejection of Replimune's melanoma therapy RP1 in a recent interview. Makary, who assumed the role in March 2025, has faced criticism for the agency's handling of vaccine applications, notably the initial refusal to review Moderna's mRNA flu vaccine. This decision was later reversed after intervention from the White House. Makary's tenure has also been characterized by the controversial Commissioner’s National Priority Voucher program, which has faced legal scrutiny. The FDA has seen significant leadership turnover, with Vinay Prasad, a key figure, recently stepping down as the head of the Center for Biologics Evaluation and Research. 
